Current Status of Molecular Biomarkers in Endometrial Cancer

In spite of the high and increasing incidence of endometrial cancer, our current models for prediction of prognosis and even more treatment response are suboptimal, and molecular biomarkers to assist clinical decision making are needed. In this review an overview is given of the currently known as w...

Full description

Saved in:
Bibliographic Details
Published in:Current oncology reports 2014-09, Vol.16 (9), p.403-403, Article 403
Main Authors: Werner, H. M. J., Salvesen, H. B.
Format: Article
Language:English
Subjects:
Biomarkers, Tumor - analysis
Biomarkers, Tumor - genetics
DNA, Neoplasm - genetics
Endometrial Neoplasms - diagnosis
Endometrial Neoplasms - genetics
Female
Genes, p53
Gynecologic Cancers (NS Reed
Humans
Medicine
Medicine & Public Health
Oncology
Ploidies
Predictive Value of Tests
Prognosis
Section Editor
Topical Collection on Gynecologic Cancers
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c438t-1e1f81c6d88d52abd16d3eb6abaed398b147b931cec9b61f9c77d1b6f38683ec3
cites cdi_FETCH-LOGICAL-c438t-1e1f81c6d88d52abd16d3eb6abaed398b147b931cec9b61f9c77d1b6f38683ec3
container_end_page 403
container_issue 9
container_start_page 403
container_title Current oncology reports
container_volume 16
creator Werner, H. M. J.
Salvesen, H. B.
description In spite of the high and increasing incidence of endometrial cancer, our current models for prediction of prognosis and even more treatment response are suboptimal, and molecular biomarkers to assist clinical decision making are needed. In this review an overview is given of the currently known as well as promising prognostic and predictive biomarkers in endometrial carcinoma. Key clinical challenges, where use of molecular biomarkers can meet clinical needs, are highlighted. The current status for the presently most promising prognostic and predictive biomarkers in endometrial carcinoma is reviewed. DNA ploidy, p53 status, hormone receptor level, HER2, stathmin, L1 cell adhesion molecule expression and other biomarkers are discussed in relation to the scientific robustness of various essential steps in biomarker development and (current) clinical applicability for individualizing treatment strategies. Tumour heterogeneity and its consequences for biomarker assessment and the importance of developing standardised tests for implementation are discussed. To improve the development and clinical uptake of biomarkers, several strategies are proposed.
doi_str_mv 10.1007/s11912-014-0403-3
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1549178655</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1549178655</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-1e1f81c6d88d52abd16d3eb6abaed398b147b931cec9b61f9c77d1b6f38683ec3</originalsourceid><addsrcrecordid>eNp1kE1LxDAQhoMorq7-AC9S8OKlmmnaNAEvWtYPWPGgnkOaTKVrt12T9uC_N6WriOApQ-aZN5mHkBOgF0BpfukBJCQxhTSmKWUx2yEHkLE05gmXu2OdhMtc0hk59H5FaUKpoPtklmSUp5nID8hVMTiHbR8997offNRV0WPXoBka7aKbultr947OR3UbLVrbrbF3tW6iQrcG3RHZq3Tj8Xh7zsnr7eKluI-XT3cPxfUyNikTfQwIlQDDrRA2S3RpgVuGJdelRsukKCHNS8nAoJElh0qaPLdQ8ooJLhgaNifnU-7GdR8D-l6ta2-waXSL3eAVZKmEXPAsC-jZH3TVDa4Nv1MQ-nkiUxgpmCjjOu8dVmrj6rDqpwKqRrVqUquCWjWqVSzMnG6Th3KN9mfi22UAkgnwodW-ofv19L-pX6msgso</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1655729415</pqid></control><display><type>article</type><title>Current Status of Molecular Biomarkers in Endometrial Cancer</title><source>Springer Link</source><creator>Werner, H. M. J. ; Salvesen, H. B.</creator><creatorcontrib>Werner, H. M. J. ; Salvesen, H. B.</creatorcontrib><description>In spite of the high and increasing incidence of endometrial cancer, our current models for prediction of prognosis and even more treatment response are suboptimal, and molecular biomarkers to assist clinical decision making are needed. In this review an overview is given of the currently known as well as promising prognostic and predictive biomarkers in endometrial carcinoma. Key clinical challenges, where use of molecular biomarkers can meet clinical needs, are highlighted. The current status for the presently most promising prognostic and predictive biomarkers in endometrial carcinoma is reviewed. DNA ploidy, p53 status, hormone receptor level, HER2, stathmin, L1 cell adhesion molecule expression and other biomarkers are discussed in relation to the scientific robustness of various essential steps in biomarker development and (current) clinical applicability for individualizing treatment strategies. Tumour heterogeneity and its consequences for biomarker assessment and the importance of developing standardised tests for implementation are discussed. To improve the development and clinical uptake of biomarkers, several strategies are proposed.</description><identifier>ISSN: 1523-3790</identifier><identifier>EISSN: 1534-6269</identifier><identifier>DOI: 10.1007/s11912-014-0403-3</identifier><identifier>PMID: 25064587</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Biomarkers, Tumor - analysis ; Biomarkers, Tumor - genetics ; DNA, Neoplasm - genetics ; Endometrial Neoplasms - diagnosis ; Endometrial Neoplasms - genetics ; Female ; Genes, p53 ; Gynecologic Cancers (NS Reed ; Humans ; Medicine ; Medicine &amp; Public Health ; Oncology ; Ploidies ; Predictive Value of Tests ; Prognosis ; Section Editor ; Topical Collection on Gynecologic Cancers</subject><ispartof>Current oncology reports, 2014-09, Vol.16 (9), p.403-403, Article 403</ispartof><rights>Springer Science+Business Media New York 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-1e1f81c6d88d52abd16d3eb6abaed398b147b931cec9b61f9c77d1b6f38683ec3</citedby><cites>FETCH-LOGICAL-c438t-1e1f81c6d88d52abd16d3eb6abaed398b147b931cec9b61f9c77d1b6f38683ec3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25064587$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Werner, H. M. J.</creatorcontrib><creatorcontrib>Salvesen, H. B.</creatorcontrib><title>Current Status of Molecular Biomarkers in Endometrial Cancer</title><title>Current oncology reports</title><addtitle>Curr Oncol Rep</addtitle><addtitle>Curr Oncol Rep</addtitle><description>In spite of the high and increasing incidence of endometrial cancer, our current models for prediction of prognosis and even more treatment response are suboptimal, and molecular biomarkers to assist clinical decision making are needed. In this review an overview is given of the currently known as well as promising prognostic and predictive biomarkers in endometrial carcinoma. Key clinical challenges, where use of molecular biomarkers can meet clinical needs, are highlighted. The current status for the presently most promising prognostic and predictive biomarkers in endometrial carcinoma is reviewed. DNA ploidy, p53 status, hormone receptor level, HER2, stathmin, L1 cell adhesion molecule expression and other biomarkers are discussed in relation to the scientific robustness of various essential steps in biomarker development and (current) clinical applicability for individualizing treatment strategies. Tumour heterogeneity and its consequences for biomarker assessment and the importance of developing standardised tests for implementation are discussed. To improve the development and clinical uptake of biomarkers, several strategies are proposed.</description><subject>Biomarkers, Tumor - analysis</subject><subject>Biomarkers, Tumor - genetics</subject><subject>DNA, Neoplasm - genetics</subject><subject>Endometrial Neoplasms - diagnosis</subject><subject>Endometrial Neoplasms - genetics</subject><subject>Female</subject><subject>Genes, p53</subject><subject>Gynecologic Cancers (NS Reed</subject><subject>Humans</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Oncology</subject><subject>Ploidies</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Section Editor</subject><subject>Topical Collection on Gynecologic Cancers</subject><issn>1523-3790</issn><issn>1534-6269</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNp1kE1LxDAQhoMorq7-AC9S8OKlmmnaNAEvWtYPWPGgnkOaTKVrt12T9uC_N6WriOApQ-aZN5mHkBOgF0BpfukBJCQxhTSmKWUx2yEHkLE05gmXu2OdhMtc0hk59H5FaUKpoPtklmSUp5nID8hVMTiHbR8997offNRV0WPXoBka7aKbultr947OR3UbLVrbrbF3tW6iQrcG3RHZq3Tj8Xh7zsnr7eKluI-XT3cPxfUyNikTfQwIlQDDrRA2S3RpgVuGJdelRsukKCHNS8nAoJElh0qaPLdQ8ooJLhgaNifnU-7GdR8D-l6ta2-waXSL3eAVZKmEXPAsC-jZH3TVDa4Nv1MQ-nkiUxgpmCjjOu8dVmrj6rDqpwKqRrVqUquCWjWqVSzMnG6Th3KN9mfi22UAkgnwodW-ofv19L-pX6msgso</recordid><startdate>20140901</startdate><enddate>20140901</enddate><creator>Werner, H. M. J.</creator><creator>Salvesen, H. B.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20140901</creationdate><title>Current Status of Molecular Biomarkers in Endometrial Cancer</title><author>Werner, H. M. J. ; Salvesen, H. B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-1e1f81c6d88d52abd16d3eb6abaed398b147b931cec9b61f9c77d1b6f38683ec3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Biomarkers, Tumor - analysis</topic><topic>Biomarkers, Tumor - genetics</topic><topic>DNA, Neoplasm - genetics</topic><topic>Endometrial Neoplasms - diagnosis</topic><topic>Endometrial Neoplasms - genetics</topic><topic>Female</topic><topic>Genes, p53</topic><topic>Gynecologic Cancers (NS Reed</topic><topic>Humans</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Oncology</topic><topic>Ploidies</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Section Editor</topic><topic>Topical Collection on Gynecologic Cancers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Werner, H. M. J.</creatorcontrib><creatorcontrib>Salvesen, H. B.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Biological Science Journals</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Current oncology reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Werner, H. M. J.</au><au>Salvesen, H. B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Current Status of Molecular Biomarkers in Endometrial Cancer</atitle><jtitle>Current oncology reports</jtitle><stitle>Curr Oncol Rep</stitle><addtitle>Curr Oncol Rep</addtitle><date>2014-09-01</date><risdate>2014</risdate><volume>16</volume><issue>9</issue><spage>403</spage><epage>403</epage><pages>403-403</pages><artnum>403</artnum><issn>1523-3790</issn><eissn>1534-6269</eissn><abstract>In spite of the high and increasing incidence of endometrial cancer, our current models for prediction of prognosis and even more treatment response are suboptimal, and molecular biomarkers to assist clinical decision making are needed. In this review an overview is given of the currently known as well as promising prognostic and predictive biomarkers in endometrial carcinoma. Key clinical challenges, where use of molecular biomarkers can meet clinical needs, are highlighted. The current status for the presently most promising prognostic and predictive biomarkers in endometrial carcinoma is reviewed. DNA ploidy, p53 status, hormone receptor level, HER2, stathmin, L1 cell adhesion molecule expression and other biomarkers are discussed in relation to the scientific robustness of various essential steps in biomarker development and (current) clinical applicability for individualizing treatment strategies. Tumour heterogeneity and its consequences for biomarker assessment and the importance of developing standardised tests for implementation are discussed. To improve the development and clinical uptake of biomarkers, several strategies are proposed.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>25064587</pmid><doi>10.1007/s11912-014-0403-3</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1523-3790
ispartof Current oncology reports, 2014-09, Vol.16 (9), p.403-403, Article 403
issn 1523-3790
1534-6269
language eng
recordid cdi_proquest_miscellaneous_1549178655
source Springer Link
subjects Biomarkers, Tumor - analysis
Biomarkers, Tumor - genetics
DNA, Neoplasm - genetics
Endometrial Neoplasms - diagnosis
Endometrial Neoplasms - genetics
Female
Genes, p53
Gynecologic Cancers (NS Reed
Humans
Medicine
Medicine & Public Health
Oncology
Ploidies
Predictive Value of Tests
Prognosis
Section Editor
Topical Collection on Gynecologic Cancers
title Current Status of Molecular Biomarkers in Endometrial Cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T00%3A27%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Current%20Status%20of%20Molecular%20Biomarkers%20in%20Endometrial%20Cancer&rft.jtitle=Current%20oncology%20reports&rft.au=Werner,%20H.%20M.%20J.&rft.date=2014-09-01&rft.volume=16&rft.issue=9&rft.spage=403&rft.epage=403&rft.pages=403-403&rft.artnum=403&rft.issn=1523-3790&rft.eissn=1534-6269&rft_id=info:doi/10.1007/s11912-014-0403-3&rft_dat=%3Cproquest_cross%3E1549178655%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c438t-1e1f81c6d88d52abd16d3eb6abaed398b147b931cec9b61f9c77d1b6f38683ec3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1655729415&rft_id=info:pmid/25064587&rfr_iscdi=true